Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 April 2020Website:
http://www.oricpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
ORIC Latest News
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 3, 2024 (the “Grant Date”), ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June:
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in April:
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Oric Pharmaceuticals, Inc. (ORIC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:
If you are looking for stocks that are well positioned to maintain their recent uptrend, Oric Pharmaceuticals, Inc. (ORIC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Under most financial guidance frameworks, experts advise a long-term approach, which is exactly the opposite ethos when it comes to speculative ideas for high potential stocks. Here, the emphasis centers on getting in, scalping a quick profit and getting out to advantage the next opportunity.
ORIC Pharma's stock has nearly doubled after positive data from its second candidate, ORIC-114, which has shown a best-in-class profile. ORIC-114 has demonstrated minimal toxicity, CNS activity, and systemic activity in patients with EGFR or HER2 exon 20 mutated non-small cell lung cancer. The drug has the potential to address the unmet need for effective CNS accessing medicines in NSCLC patients with brain metastases.
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers
What type of business is ORIC Pharmaceuticals?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
What sector is ORIC Pharmaceuticals in?
ORIC Pharmaceuticals is in the Healthcare sector
What industry is ORIC Pharmaceuticals in?
ORIC Pharmaceuticals is in the Biotechnology industry
What country is ORIC Pharmaceuticals from?
ORIC Pharmaceuticals is headquartered in United States
When did ORIC Pharmaceuticals go public?
ORIC Pharmaceuticals initial public offering (IPO) was on 24 April 2020
What is ORIC Pharmaceuticals website?
https://www.oricpharma.com
Is ORIC Pharmaceuticals in the S&P 500?
No, ORIC Pharmaceuticals is not included in the S&P 500 index
Is ORIC Pharmaceuticals in the NASDAQ 100?
No, ORIC Pharmaceuticals is not included in the NASDAQ 100 index
Is ORIC Pharmaceuticals in the Dow Jones?
No, ORIC Pharmaceuticals is not included in the Dow Jones index
When does ORIC Pharmaceuticals report earnings?
The next expected earnings date for ORIC Pharmaceuticals is 09 August 2024